Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Avita Medical, de nieuwe parel.

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Avita Medical, de nieuwe parel.

269 Posts
Pagina: «« 1 2 3 4 5 6 ... 14 »» | Laatste | Omlaag ↓
  4. uptech 11 januari 2019 11:46
    Lang geleden heb ik ook aandelen Pharming gehad en volgde het forum. Maar idd, niet te doen dat forum. Gevuld met mensen die alleen maar bezig zijn om hun gelijk te halen en elkaar de vlooien afvangen. En veel posters die last hebben van het Calimero syndroom: veel verontwaardiging over " de shorters" en " de grote jongens" die volgens betrokkenen de koers bepalen en waar ze niets tegen kunnen doen. " En da's nie eerlijk!"
  10. peebee 23 januari 2019 11:50
    quote:

    uptech schreef op 23 januari 2019 10:37:

    Bijna nergens valt iets te vinden over de notering op de beurs in Frankfurt. Op de site van Avita wordt alleen gesproken over de Australische en Otc notering. Ik heb een mail gestuurd en gevraagd om uitleg,maar nog geen antwoord gekregen
    kun je je antwoord posten, aub...
    volg het aandeel bijna dagelijks, nu!

    kijk zelf veel op avita forum yahoo, maar daar weinig info of postings..
  12. peebee 28 januari 2019 10:00
    Ik heb in totaal 3 koersen voor Avita in mijn tel staan..

    nu:
    AVMXF: $ 0,10
    AVMXY: $ 1,67
    GCR.F: € 0,059

    telkens grote valuaties in de koers, dus ben zeer benieuwd naar het antwoord vanuit Avita..
    Heb ze ook in Duitsland gekocht, maar misschien beter om in USA te kopen, daar is het te doen voor ze...

    Neemt niet weg dat de toekomst er florissant uitziet voor dit bedrijf...

  13. frank2you 29 januari 2019 13:33
    200 mln. ?

    De brandwondenmarkt is veel groter dan dat in de VS alleen. En dan praat ik nog niet over de EU en andere continenten plus andere toepassingen.

    Koersdoel korte-middellange termijn paar honderd %
    Koersdoel lange termijn paar duizend %

    Dit zijn zeer realistische schattingen/berekeningen.
  16. Omnius 29 januari 2019 19:30
    vanmorgen in de mail:
    AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting

    RECELL System clinical benefits and cost savings featured in 26 presentations
    at four burn conferences in early 2019

    Valencia, Calif., USA, and Melbourne, Australia, 29 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that 26 abstracts highlighting the clinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device (RECELL® System) have been selected for presentation at four burn conferences in early 2019. Nine of the presentations will be made at the largest burn conference, the American Burn Association (ABA) 51st Annual Meeting to be held in Las Vegas April 2-5, 2019, including a Top-Five Abstract presentation in plenary session. Each of the presentations will be made by clinical investigators who will share their experiences and observations treating patients with the RECELL System.

    NINE PRESENTATIONS AT ABA MEETING

    The nine presentations at the ABA meeting include the clinical results and benefits of the RECELL System in the treatment of burns in specific subgroups of patients and types of burn injuries, including:
    Pediatric patients (selected as a Top-Five Abstract to be presented in plenary session)
    Extensive burn injuries in an adult population (life threatening burns greater than 50 percent total body surface area or TBSA)
    Burn injuries of the hands
    Burn injuries of joints and rehabilitation considerations
    Budget impact of use of the RECELL System versus standard of care in treatment of severe burns at Arizona Burn Center
    Post-operative wound management following treatment with the RECELL System
    Treatment and healing of donor sites with the RECELL System in patient with large TBSA burns
    Case study of 60% TBSA patient with life-threatening burn injuries and limited donor skin
    A summary of ten years of clinical experience using RECELL System in the point-of-care treatment of burn injuries
    The U.S. Food and Drug Administration (FDA) approved the RECELL System in September 2018 for the treatment of acute thermal burns in patients 18 years and older. Patients included in seven of the ABA presentations were treated as part of the Compassionate Use and Continued Access Investigational Device Exemption (IDE) programs made available to more than 150 burn patients prior to the FDA approval. Several of the presentations include classes of burns or patients that fall outside of the currently approved U.S. product labeling. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

    “These abstracts build upon and greatly advance the pivotal clinical trial results and health economic data presented at last year’s ABA meeting,” said Dr. Michael Perry, Avita Medical’s Chief Executive Officer. “The presentations to be made this April at the 2019 ABA meeting highlight the positive clinical outcomes that burn surgeons have observed in a broad range of patients and burn types. The clinical results demonstrate that the RECELL System is a major innovation in the treatment of burn patients as evidenced by the prominent featuring of this product candidate at the ABA conference. We appreciate the strong support we have received from the medical professionals and patients participating in these studies and thank them for their efforts in advancing the care of burn patients.”

    NINE ADDITIONAL PRESENTATIONS MADE AT TWO BURN CONFERENCES LAST WEEK

    During the North American Burn Society 37th Annual Conference (NABS) held 20-23 January 2019 in Park City, Utah, eight presentations were made supporting the clinical and economic benefits of the RECELL System. Kevin Foster, MD, MBA, FACS, Arizona Burn Center, made a series of presentations detailing the results from two U.S. pivotal clinical trials which demonstrated the effectiveness, safety and clinical benefits of the RECELL System, and which were used as the primary basis for the FDA approval. Dr. Foster also presented a case study of the successful treatment with the RECELL System of a patient with a large soft-tissue defect caused by necrotizing fasciitis, or flesh-eating bacteria. Other presentations at the NABS conference included:
    An overview of the protocols for two randomized controlled U.S. trials of the RECELL System in the treatment of pediatric patients
    A case study of the successful treatment of a 60% TBSA burn patient with the RECELL System in combination with a biodegradable temporizing matrix
    At the LA-ACS/SAL Annual Meeting held 18-20 January 2019 in New Orleans, Louisiana, Blake Platt, MD, University Medical Center New Orleans Burn Center and LSU Health New Orleans School of Medicine, presented data demonstrating a reduction in length of stay for burn patients treated with the RECELL System. Dr. Platt presented the results of 18 patients treated in the Compassionate Use and Continued Access programs who had a mean length of stay of 24 days compared to the expected mean length of stay of 55 days based on data from the American Burn Association National Burn Repository, a greater than 50 percent reduction.

    EIGHT PRESENTATIONS AT UPCOMING JOHN A BOSWICK BURN & WOUND SYMPOSIUM

    An additional eight presentations have been accepted for presentation at the John A Boswick Burn & Wound Symposium to be held 2-7 February 2019 in Maui. These describe the clinical and cost savings benefits of treatment with the RECELL System, and the presentations include:
    Pivotal trials in 2nd and 3rd degree burns
    Health economic model demonstrating cost savings benefit of the RECELL System
    Treatment with the RECELL System combined with dermal substitutes
  17. Omnius 31 januari 2019 09:53
    avitamedical.com/uploads/pdf/AVH-Pres...

    Avita Medical Second Quarter Fiscal 2019
    Quarterly Cash Flow Report and Company Update
    Recent Highlights
    • Pre-launch U.S. product sales of A$1.1 million in second quarter
    • Successful preparation for U.S. national market launch in January 2019
    • 26 abstracts highlighting RECELL® System clinical and economic benefits accepted for presentation at
    multiple burn conferences, including the American Burn Association (ABA) 51st Annual Meeting
    • A$41.7 million equity financing provide resources for U.S. launch and pipeline expansion

    ....
  18. frank2you 5 februari 2019 11:48
    9,1 cent wat een ontwikkeling sinds nov.dec. vorig jaar. En dit is nog maar het begin. Ik ben erg voorzichtig als ik zeg dat 100% rendement dit jaar wel het minimale is. Laat het salesteam haar werk doen, het middel de patienten en artsen overtuigen en de cijfers de budgethouders.
269 Posts
Pagina: «« 1 2 3 4 5 6 ... 14 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 874,79 +0,96%
EUR/USD 1,0706 +0,50%
FTSE 100 8.044,81 +0,26%
Germany40^ 18.165,10 +1,70%
Gold spot 2.328,57 +0,06%
NY-Nasdaq Composite 15.451,31 +1,11%

Stijgers

VIVORY...
+26,32%
BAM
+4,73%
PROSUS
+3,52%
ASMI
+3,14%
JUST E...
+3,10%

Dalers

RANDST...
-7,22%
Akzo N...
-6,93%
FASTNED
-4,65%
NSI
-3,89%
Arcelo...
-2,65%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!